Norges Bank
AEGR

Norges Bank’s Aegerion Pharmaceuticals AEGR Stock Holding History

Norges Bank’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-72,473
Closed -$986K – 2288
2015
Q3 		$986K Buy
72,473
+56,561
+355% +$1.01M ﹤0.01% 2115
2015
Q2 		$302K Buy
+15,912
New +$344K ﹤0.01% 2216
2015
Q1 		– Sell
-213,699
Closed -$4.47M – 2351
2014
Q4 		$4.47M Buy
213,699
+49,762
+30% +$1.25M ﹤0.01% 1945
2014
Q3 		$5.47M Buy
163,937
+159,137
+3,315% +$4.94M ﹤0.01% 1890
2014
Q2 		$154K Buy
+4,800
New +$179K ﹤0.01% 2231

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Norges Bank's AEGR Position: Q4 2015 in Review

Norges Bank sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 72,473 shares — an estimated $986K sold.

Norges Bank first reported a position in AEGR in Q2 2014 and held it in 5 quarters. The position peaked at $5.47M in Q3 2014. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • Norges Bank reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Norges Bank sold 72,473 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $986K.
  • Norges Bank first reported a position in Aegerion Pharmaceuticals in Q2 2014 and held it in 5 quarters.
  • Norges Bank's Aegerion Pharmaceuticals position peaked at $5.47M in Q3 2014.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on Norges Bank's 13F filing for Q4 2015, filed 10 Feb 2016.